AI is moving beyond experimental research into the everyday operations of drug development, automating repetitive tasks while keeping human experts in control of critical decisions. Two major initiatives announced this week show how pharmaceutical companies and biotech firms are integrating artificial intelligence into workflows that span laboratory research, clinical trials, and regulatory compliance. Rather than replacing scientists, these tools are designed to free them from tedious administrative work so they can focus on the science that matters most.

What Does AI-Powered Drug Development Actually Look Like?

Thermo Fisher Scientific, one of the world's largest life sciences companies, is rolling out a suite of AI-enabled tools across its research and manufacturing divisions. The company announced strategic partnerships with technology firms including NVIDIA, OpenAI, TetraScience, and BenchSci to help pharmaceutical customers improve experimental design, automate laboratory workflows, and extract deeper insights from complex scientific data. These integrations are designed to work within existing laboratory environments, connecting data across different instruments and research platforms to create a unified, data-driven approach to drug discovery.

The company is also expanding its Accelerator Drug Development program, which combines scientific expertise, AI-enabled workflows, laboratory technologies, and development capabilities to help emerging biotech companies move more efficiently from discovery through clinical development. Additionally, Thermo Fisher acquired two software companies, MSAID and Proteinaceous, to strengthen its proteomics ecosystem by adding machine learning and advanced analysis capabilities that help scientists interpret large-scale datasets faster and with greater confidence.

How Are Pharmaceutical Companies Using AI for Regulatory Documents?

Beyond the laboratory, AI is now assisting with one of the most time-consuming aspects of drug development: writing regulatory documents. Cancer Research UK's Centre for Drug Development recently partnered with TrialAssure, a clinical trial technology company, to use an AI tool called LINK AI to support the creation of regulatory and clinical trial documents. The collaboration demonstrates a practical, human-centered approach to AI adoption in medical writing.

The process works through what experts call a "human-in-the-loop" model. Medical writing teams at Cancer Research UK use LINK AI to generate initial drafts of regulatory documents, including Investigator's Brochures, Clinical Study Reports, and patient narratives. However, experienced medical writers review, refine, and finalize every output before submission. The organization is starting with defined workflows and adapting the AI's prompts to match existing internal templates and instructional guidelines.

"AI adoption in medical writing succeeds when the technology fits the way expert teams already work. Our work with the incredible team at Cancer Research UK shows how organizations can use AI thoughtfully, starting with defined workflows, adapting prompts to existing templates, and giving medical writers the ability to review and shape every output," said Zach Weingarden, Director of AI Technology and Applications at TrialAssure.

Zach Weingarden, Director of AI Technology and Applications at TrialAssure

Why Are Pharma Companies Investing in AI Now?

The pharmaceutical industry faces mounting pressure to accelerate drug development timelines while managing increasingly complex research portfolios. As demand grows for advanced therapies, including combination agents, multi-region submissions, and precision medicine platform trials, the volume of regulatory documents and experimental data is overwhelming traditional workflows. AI tools are positioned as a solution to this bottleneck.

For Cancer Research UK's Centre for Drug Development, which has completed over 170 clinical trials and brought six new agents to market over 30 years, the challenge is clear. The organization's ambition to bring more innovative treatments to cancer patients requires more efficient ways of working. By automating repetitive document drafting and data analysis tasks, medical writers and scientists can focus on the critical scientific content that requires human judgment and expertise.

"Partnering with TrialAssure allows us to explore how generative AI can streamline document authoring and free up our experts to focus on critical scientific content, helping CDD accelerate the delivery of cutting-edge treatments, including those targeting rare and hard-to-treat cancers," stated Amber Holmes, Head of Quality, Regulatory, Pharmacovigilance and Medical Writing at Cancer Research UK's Centre for Drug Development.

Amber Holmes, Head of Quality, Regulatory, Pharmacovigilance and Medical Writing at Cancer Research UK's Centre for Drug Development

Steps to Implement AI in Drug Development Workflows

• Start with Defined Workflows: Identify specific, repetitive tasks where AI can add immediate value, such as initial document drafting or data interpretation, rather than attempting to overhaul entire research operations at once.
• Customize AI Tools to Existing Processes: Adapt AI prompts and configurations to match internal templates, instructional guidelines, and organizational standards so the technology integrates seamlessly with how teams already work.
• Maintain Human Oversight: Establish a structured review process where experienced scientists, medical writers, or regulatory experts evaluate and refine all AI-generated outputs before they are used or submitted to regulators.
• Build Cross-Functional Partnerships: Work closely with technology providers to understand organizational needs, establish clear implementation timelines, and ensure the AI solution meets rigorous requirements for regulated life sciences work.

What Specific AI Capabilities Are Being Deployed?

Thermo Fisher's investments span multiple dimensions of drug development. The company is expanding its global Bioprocess Design Center network with new facilities in the United States and India, complementing existing centers in China, Korea, and Singapore. These centers provide customers with local expertise, advanced bioprocessing technologies, technical consulting, and collaborative laboratory environments to streamline process development and improve manufacturing readiness.

In manufacturing, Thermo Fisher is launching new GMP (Good Manufacturing Practice) monoclonal antibody manufacturing capabilities in Plainville, Massachusetts, in the second half of 2026, supporting large-scale production of monoclonal antibody therapies across multiple disease indications. The company is also expanding sterile fill-finish and device assembly capacity, oral solid dose manufacturing capabilities, and biologics drug substance capacity across global facilities.

On the clinical development side, Thermo Fisher acquired Clario Holdings Inc., which provides endpoint data and evidence generation solutions that have supported approximately 70 percent of FDA and EMA novel drug approvals over the past decade. The company is also expanding AI-enabled analytics and workflow solutions designed to help customers improve clinical trial efficiency, streamline interpretation of complex scientific and clinical data, and support more informed development decisions.

How Does This Change the Timeline for Getting Drugs to Patients?

The ultimate goal of these AI investments is to reduce the time and cost required to bring new therapies to patients. By automating experimental design, streamlining data analysis, and accelerating regulatory document preparation, pharmaceutical companies hope to compress development timelines without sacrificing safety or efficacy standards. However, the success of these tools depends on thoughtful implementation and maintaining human expertise at every critical decision point.

Thermo Fisher's executive leadership emphasized this point at the BIO International 2026 conference. The company positions itself as a provider of integrated solutions that help customers harness AI, scientific data, and advanced manufacturing capabilities to improve productivity, enhance decision-making, and reduce complexity across the entire drug development lifecycle. The message is clear: AI is a tool to augment human expertise, not replace it.

" }